These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11444479)

  • 1. Economic burden of NSAID-induced gastropathy in Sweden.
    Jönsson B; Haglund U
    Scand J Gastroenterol; 2001 Jul; 36(7):775-9. PubMed ID: 11444479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs.
    Vonkeman HE; Klok RM; Postma MJ; Brouwers JR; van de Laar MA
    Drugs Aging; 2007; 24(8):681-90. PubMed ID: 17702536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland.
    Delcò F; Michetti P; Beglinger C; Fried M; Szucs TD
    Digestion; 2004; 69(1):10-9. PubMed ID: 14755148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse gastrointestinal effects of NSAIDs: consequences and costs.
    Bidaut-Russell M; Gabriel SE
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):739-53. PubMed ID: 11566038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis.
    El-Serag HB; Graham DY; Richardson P; Inadomi JM
    Arch Intern Med; 2002 Oct; 162(18):2105-10. PubMed ID: 12374519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of non-steroidal anti-inflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease.
    Voutilainen M; Mäntynen T; Färkkilä M; Juhola M; Sipponen P
    Scand J Gastroenterol; 2001 Aug; 36(8):817-21. PubMed ID: 11495076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The iatrogenic cost of non-steroidal anti-inflammatory drug therapy.
    De Pouvourville G
    Br J Rheumatol; 1995 Apr; 34 Suppl 1():19-24. PubMed ID: 7780675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Critical evaluation of economic analysis exemplified by preventive misoprostol administration in antirheumatic drug-induced gastropathy].
    Stucki G; Sangha O
    Z Rheumatol; 1994; 53(1):37-45. PubMed ID: 8165876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation.
    Johnson RE; Hornbrook MC; Hooker RS; Woodson GT; Shneidman R
    Pharmacoeconomics; 1997 Jul; 12(1):76-88. PubMed ID: 10169389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury.
    Griffin MR
    Am J Med; 1998 Mar; 104(3A):23S-29S; discussion 41S-42S. PubMed ID: 9572317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From peptic ulcer disease to NSAID gastropathy. An evolving nosology.
    Roth SH
    Drugs Aging; 1995 May; 6(5):358-67. PubMed ID: 7647425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands.
    Herings RM; Klungel OH
    Pharmacoeconomics; 2001; 19(6):655-65. PubMed ID: 11456213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes: the cost of illness in Sweden.
    Henriksson F; Jönsson B
    J Intern Med; 1998 Dec; 244(6):461-8. PubMed ID: 9893099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of NSAID induced peptic ulcer disease.
    Hamid S; Yakoob J; Jafri W; Islam S; Abid S; Islam M
    J Pak Med Assoc; 2006 May; 56(5):218-22. PubMed ID: 16767948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aggressiveness of NSAIDs versus digestive system mucosa].
    Sternon J
    Rev Med Brux; 1992 Dec; 13(10):355-9. PubMed ID: 1480886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory drug gastropathy.
    Laine L
    Gastrointest Endosc Clin N Am; 1996 Jul; 6(3):489-504. PubMed ID: 8803564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
    Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
    Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis.
    Steen KS; Lems WF; Aertsen J; Bezemer D; Dijkmans BA
    Ann Rheum Dis; 2001 May; 60(5):443-7. PubMed ID: 11302864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NSAID-induced ulcers and prophylaxis. A reappraisal.
    Farr CM
    J Clin Gastroenterol; 1993 Oct; 17(3):187-8. PubMed ID: 8228076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.